Ornithine-δ-aminotransferase clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, not yet accepting patients
The Gyrate Atrophy Ocular and Systemic Study characterizes the natural history of ornithine levels and retinal degeneration (RD) associated with disease-causing OAT variants in the presence of standard care dietary treatment regimens over 4 years. The research goal is to understand the impact of OAT mutations on plasma ornithine levels and retinal degeneration.
San Francisco, California and other locations
Our lead scientists for Ornithine-δ-aminotransferase research studies include Jacque Duncan, MD.